Safety and Efficacy of IDA for Onchocerciasis

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

March 14, 2022

Study Completion Date

June 1, 2022

Conditions
Onchocerciasis
Interventions
DRUG

IVM w/ ALB

Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)

DRUG

Single dose of IDA

Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)

DRUG

Three daily doses of IDA

Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)

Trial Locations (1)

Unknown

University of Health and Allied Sciences, Hohoe

All Listed Sponsors
collaborator

Case Western Reserve University

OTHER

collaborator

University of Health and Allied Sciences

OTHER

lead

Washington University School of Medicine

OTHER

NCT04188301 - Safety and Efficacy of IDA for Onchocerciasis | Biotech Hunter | Biotech Hunter